Effect of varying nitric oxide release to prevent platelet consumption and preserve platelet function in an in vivo model of extracorporeal circulation
Restricted accessResearch articleFirst published online May, 2007
Effect of varying nitric oxide release to prevent platelet consumption and preserve platelet function in an in vivo model of extracorporeal circulation
The gold standard for anticoagulation during extracorporeal circulation (ECC) remains systemic heparinization and the concomitant risk of bleeding in an already critically ill patient could lead to death. Normal endothelium is a unique surface that prevents thrombosis by the release of antiplatelet and antithrombin agents. Nitric oxide (NO) is one of the most potent, reversible antiplatelet agents released from the endothelium. Nitric oxide released from within a polymer matrix has been proven effective for preventing platelet activation and adhesion onto extracorporeal circuits. However, the critical NO release (NO flux) threshold for thrombus prevention during ECC has not yet been determined.1 Using a 4-hour arteriovenous (AV) rabbit model of ECC,2 we sought to find this threshold value for ECC circuits, using an improved NO-releasing coating (Norel-b ). Four groups of animals were tested at variable NO flux levels. Hourly blood samples were obtained for measurement of arterial blood gases, platelet counts, fibrinogen levels and platelet function (via aggregometry). A custom-built AV circuit was constructed with 36 cm of poly(vinyl)chloride (PVC) tubing, a 14 gauge (GA) angiocatheter for arterial access and a modified 10 French (Fr) thoracic catheter for venous access. The Norel-b coating reduced platelet activation and thrombus formation, and preserved platelet function — in all circuits that exhibited an NO flux of 13.65 × 10— 10 mol·cm—2·min—1. These results were significant when compared with the controls. With the Norel-b coating, the NO flux from the extracorporeal circuit surface can be precisely controlled by the composition of the polymer coating used, and such coatings are shown to prevent platelet consumption and thrombus formation while preserving platelet function in the animal.Perfusion (2007) 22, 193—200.
Get full access to this article
View all access options for this article.
References
1.
Miskulin J., Annich G., Gillian C., et al. NO flux determines thromboresistance in NO-releasing extracorporeal circuits. ASAIO J2002; 48(2): 145 (poster presentation ASAIO, New York2002).
2.
Skrzypchak AM , Miskulin J., Bartlett RH, Annich GMThe development of a small animal model of extracorporeal circulation. ASAIO J2006; 52(3): 296—302.
3.
van Oeveren W., Wildevuur Crh.Blood compatibility of cardiopulmonary bypass circuits. Perfusion1987; 2: 237—44.
4.
Gallimore MJ , Heller W., Fuhrer G., Wendel HP, Klaffschenkel R., Hoffmeister HEContact activation, heparins and cardiopulmonary bypass. Thromb Haemost1992; 68: 91—92.
5.
Hennessy Jr. VL, Hicks RE, Nierwiarowski S., et al. Function of human platelets during extracorporeal circulation. Am J Physiol1997 ; 232: H622—H628.
6.
Robinson TM, Kickler TS, Walker LK, et al. Effect of extracorporeal membrane oxygenation on platelets in newborns. Crit Care Med1983; 21: 1029—34.
7.
ECMO Registry of the Extracorporeal Life Support Organization (ELSO), Ann Arbor, Michigan, April, 2006.
8.
Gorman RC, Ziats NP, Rao AK, et al. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg1996; 112: 557—58.
9.
EdmundsJr. LH, Stenach N. The blood-surface interface. In Gravlee GP, Davis RF, Kurusz M, Utley JR eds. Cardiopulmonary bypass, principles and practice. 2nd edn. Pennsylvania, Williams & Wilkins, 1999: 150—66.
10.
Plotz FB, Wildevuur WR, Wildevuur Crh, et al. Platelet consumption during neonatal extracorporeal life support (ECLS). Perfusion1992; 7: 27—32.
11.
Salzman EW, Rosenberg RD, Smith MH, et al. Effect of heparin and heparin fractions on platelet aggregation . J Clin Invest1980; 65: 64—73.
12.
Annich GM, Meinhardt JP, Mowery KA, et al. Reduced platelet activation and thrombosis in extracorporeal circuits coated with nitric oxide release polymers. Crit Care Med2000; 28(4): 915—20.
Moncada S., Palmer Rmj.Biosynthesis and actions of nitric oxide. Semin Perinatol1991; 15:16—19.
15.
Radomski MW , Moncada S.The biological and pharmacological role of nitric oxide in platelet function. Adv Exp Med Biol1993; 344: 251—65.
16.
Radomski MW , Palmer RM, Moncada S.The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun1987; 148(3): 1482—89.
17.
Vaughn MW, Kuo L., Liao JCEstimation of nitric oxide production and reaction rates in tissue by use of a mathematical model. Am. J Physiol1998 ; 274: H2163—76.
18.
Zhang H., Merz SI, Annich GM, et al. Nitric oxide releasing silicone rubbers with improved blood compatibility: preparation, characterization, and in vivo evaluations. Biomaterials2002; 23: 1485—94.
19.
Zhang H., Annich GM, Miskulin J., et al. Nitric oxide-releasing fumed silica particles: synthesis, characterization, and biomedical application. J Am Chem Soc2003; 125: 5015—24.
20.
Weiss DJComparative physiology of platelets from different species. In Rao HR ed. Handbook of platelet physiology and pharmacology. Boston, Kluwer Academic Publishers, 1999: 379—93.
21.
Day HJ, Rao AKEvaluation of platelet function. Semin Hematol1986; 23(2): 89—101.
22.
Espadas-Torre C.Controlled release of platelet— inhibiting nitric oxide from functional polymeric ion-selective membranes containing nitric oxide donors. [Doctoral Thesis]Ann Arbor, MI, University of Michigan, 1996: 70—108.
23.
Haisch CE, Parker F., Brown P.Section XII Chapter 69: Vascular. In Sabiston text of surgery , 17th edn. Townsend, Saunders, 2004: 2089—90.
24.
Gorbet MB, Sefton MVBiomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials2004 ; 25: 5681—703.
25.
Blackstone EH , Kirklin JW, Stewart RW, Chenoweth DEThe damaging effects of cardiopulmonary bypass . In Wu KK, Roxy EC eds. Prostaglandins in clinical medicine: cardiovascular and thrombotic disorders. Chicago, Yearbook Medical Publishers Inc., 1982: 355.
26.
Fleser PS, Nuthakki VK, Malinzak LE, et al. Nitric oxide releasing biopolymers inhibit thrombus formation in a sheep model of arteriovenous bridge grafts. J Vasc Surg2004; 40: 803—11.
